Frenneredetal.BMCCancer(2021)21:447Page9of9
15.TheNorweigannationalcareprogramforanalcancer(inNorweigan).
https://www.helsedirektoratet.no/retningslinjer/analkreft-handlingsprogra
m/Analkreft%20-%20Nasjonalt%20handlingsprogram%20med%2
0retningslinjer%20for%20diagnostikk,%20behandling%20og%20oppf%C3%
B8lging.pdf/_/attachment/inline/06408501-5e87-4e0f-8249-d84877f4fca8:eea
588d8f71754f56b2a83ab1a7355439f4fb43f/Analkreft%20-%20Nasjonalt%20ha
ndlingsprogram%20med%20retningslinjer%20for%20diagnostikk,%20beha
ndling%20og%20oppf%C3%B8lging.pdf.Accessed10Aug2020.
16.TheUKnationalguidanceforIMRTinanalcancer.http://analimrtguidance.
co.uk/national-anal-imrt-guidance-v3.pdf.Accessed10Aug2020.
17.ShakirR,AdamsR,CooperR,DowningA,GehI,GilbertD,etal.
PatternsandpredictorsofrelapsefollowingChemoradiationtherapy
withasimultaneousintegratedboostinanalsquamouscellcarcinoma.
IntJRadiatOncolBiolPhys.2020;106(2):329–39.https://doi.org/10.1016/
j.ijrobp.2019.10.016.
18.BarringtonSF,KlugeR.FDGPETfortherapymonitoringinHodgkinand
non-Hodgkinlymphomas.EurJNuclMedMolImaging.2017;44(Suppl1):
97–110.https://doi.org/10.1007/s00259-017-3690-8.
19.MeignanM,GallaminiA,MeignanM,GallaminiA,HaiounC.Reportonthefirst
internationalworkshoponinterim-PET-scaninlymphoma.LeukLymphoma.
2009;50(8):1257–60.https://doi.org/10.1080/10428190903040048.
20.NilssonMP,NilssonED,JohnssonA,LeonO,GunnlaugssonA,SchermanJ.
Patternsofrecurrenceinanalcancer:adetailedanalysis.RadiatOncol.2020;
15(1):125.
21.GardaAE,NavinPJ,MerrellKW,MartensonJA,NebenWittichMA,
HaddockMG,etal.Patternsofinguinallymphnodemetastasesinanal
canalcancerandrecommendationsforelectiveclinicaltargetvolume
(CTV)delineation.RadiotherOncol.2020;149:128–33.https://doi.org/10.1
016/j.radonc.2020.05.018.
22.DapperH,SchillerK,MunchS,PeekenJC,BormK,WeberW,etal.Havewe
achievedadequaterecommendationsfortargetvolumedefinitionsinanal
cancer?APETimagingbasedpatternsoffailureanalysisinthecontextof
establishedcontouringguidelines.BMCCancer.2019;19(1):742.https://doi.
org/10.1186/s12885-019-5970-0.
23.Pa?oB,SebastiàC,Bu?eschL,MestresJ,SalvadorR,MacíasNG,etal.
Pathwaysoflymphaticspreadinmaleurogenitalpelvicmalignancies.
Radiographics.2011;31(1):135–60.https://doi.org/10.1148/rg.311105072.
24.DapperH,OechsnerM,HircheC,MunchS,SauterC,BormK,etal.
Dosimetriccomparisonofdifferentradiationtechniques(IMRTvs.3-
dimensional)ofthe"true"(deep)ano-inguinallymphaticdrainageofanal
cancerpatients.RadiatOncol.2018;13(1):227.
25.BentzenAG,GurenMG,WanderasEH,FrykholmG,TveitKM,WilsgaardT,
etal.Chemoradiotherapyofanalcarcinoma:survivalandrecurrenceinan
unselectednationalcohort.IntJRadiatOncolBiolPhys.2012;83(2):e173–80.
https://doi.org/10.1016/j.ijrobp.2011.12.062.
26.Vilarino-VarelaMJ,TaylorA,RockallAG,ReznekRH,PowellME.Averification
studyofproposedpelviclymphnodelocalisationguidelinesusing
nanoparticle-enhancedmagneticresonanceimaging.RadiotherOncol.
2008;89(2):192–6.https://doi.org/10.1016/j.radonc.2008.07.023.
27.Beets-TanRGH,LambregtsDMJ,MaasM,BipatS,BarbaroB,Curvo-Semedo
L,etal.Magneticresonanceimagingforclinicalmanagementofrectal
cancer:updatedrecommendationsfromthe2016EuropeanSocietyof
GastrointestinalandAbdominalRadiology(ESGAR)consensusmeeting.Eur
Radiol.2018;28(4):1465–75.https://doi.org/10.1007/s00330-017-5026-2.
28.GretschelS,WarnickP,BembenekA,DreselS,KoswigS,StringA,etal.
Lymphaticmappingandsentinellymphnodebiopsyinepidermoid
carcinomaoftheanalcanal.EurJSurgOncol.2008;34(8):890–4.https://doi.
org/10.1016/j.ejso.2007.11.013.
Publisher’sNote
SpringerNatureremainsneutralwithregardtojurisdictionalclaimsin
publishedmapsandinstitutionalaffiliations. |
|
